Insulet (NASDAQ:PODD – Get Free Report) had its price target boosted by equities researchers at Citigroup from $310.00 to $355.00 in a note issued to investors on Friday,Benzinga reports. The ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...

Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption ...

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...